Key result
Dexmedetomidine plus propofol reduces infarct size and preserves cardiac function after reperfusion injury in rats.
Why the study?
Although dexmedetomidine and propofol separately alleviate myocardial ischemia/reperfusion injury in rat models, the effects of their combined use remained unclear.
Does dexmedetomidine combined with propofol alleviate myocardial ischemia/reperfusion injury in a rat model?
Does dexmedetomidine combined with propofol alleviate myocardial ischemia/reperfusion injury in a rat model?
Answers are grounded in this paper and cite their sources.
The combined administration of dexmedetomidine and propofol provides synergistic protection against myocardial ischemia/reperfusion injury via activation of AMPK-mediated autophagy in a preclinical model.
Objective: Myocardial ischemia/reperfusion (MI/R) injury is a major cause of cardiac tissue damage, with high disability and death rates. Although both dexmedetomidine (Dex) and propofol (PPF) have been indicated to alleviate MI/R injury in rat models, the effects of the combined use of these two drugs remain unclear. This study aimed to investigate the combined effects of Dex and PPF against MI/R injury and related mechanisms. Methods: A rat model of MI/R injury was established and used to explore the combined effects of Dex and PPF on MI/R injury. Hematoxylin-eosin (HE) and Masson staining were used for histopathological evaluation. 2,3,5-triphenyltetrazolium chloride (TTC), echocardiography, terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) staining were used to determine myocardial infarction size, cardiac function, and apoptosis, respectively. Enzyme-linked immunosorbent assay (ELISA) was performed to assess myocardial function and oxidative stress (OS). Autophagy was observed through transmission electron microscopy. Moreover, western blotting was conducted to detect autophagy markers and the AMPK pathway. Results: The combination of Dex and PPF alleviated histopathological injury, reduced myocardial infarction, and rescued cardiac dysfunction in MI/R rats. Furthermore, Dex combined with PPF decreased the levels of MDA and ROS and increased the SOD level in MI/R rats. Besides, Dex combined with PPF inhibited myocardial apoptosis in MI/R rats. After combined treatment with Dex and PPF, the number of autophagosomes, expression levels of Beclin-1 and LC3II/LC3I were elevated, while the expression levels of p62 were reduced in MI/R rats. The combined use of Dex and PPF activated the AMPK pathway in MI/R rats. Compound C (an AMPK inhibitor) could abolish the combined effects of Dex and PPF on alleviating myocardial injury and enhancing autophagy in MI/R rats. Conclusion: The combination of Dex and PPF attenuated MI/R injury in rats, which may be associated with the activation of the AMPK signaling pathway.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2023) studied Myocardial ischemia/reperfusion (MI/R) injury (n=36). Dexmedetomidine combined with propofol vs. Model group (1% DMSO and 0.9% normal saline), dexmedetomidine alone, propofol alone was evaluated on Myocardial infarction size, cardiac function (LVEF, LVFS), and apoptosis (p=<0.01). The combination of dexmedetomidine and propofol significantly alleviated histopathological injury, reduced myocardial infarction, and rescued cardiac dysfunction in MI/R rats compared to vehicle or monotherapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: